Literature DB >> 9426440

Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma.

R Bellantone1, A Ferrante, M Boscherini, C P Lombardi, P Crucitti, F Crucitti, G Favia, D Borrelli, L Boffi, L Capussotti, G Carbone, M Casaccia, A Cavallaro, A Del Gaudio, G Dettori, V Di Giovanni, A Mazziotti, D Marrano, E Masenti, P Miccoli, F Mosca, A Mussa, R Petronio, G Piat, L Marazano.   

Abstract

BACKGROUND: Recurrence of adrenal cortical carcinoma (ACC) after radical surgery is a common finding. Although successful reoperations have been reported with encouraging results, most published experiences are anecdotal and based on few cases. We report the results of surgical treatment for recurrent ACC in a multiinstitutional series.
METHODS: One hundred eighty-eight cases of ACC were collected in a national registry. A complete follow-up was obtained in 179 cases. At initial diagnosis 92 patients had local disease (stage I or II). One hundred seventy patients underwent surgical treatment, considered radical in 140; in this group, recurrent disease was observed in 52 cases (37%) after a mean disease-free interval of 21.7 months.
RESULTS: Adjuvant chemotherapy was ineffective in ameliorating the prognosis. The mean survival in 20 patients who underwent reoperation was significantly higher (15.85 +/- 14.9 months) than in nonreoperated cases (3.2 +/- 2.9 months). Five-year actuarial survival in reoperated patients is significantly better than in nonreoperated patients (49.7% versus 8.3%, respectively).
CONCLUSIONS: Although the prognosis of this tumor is still poor, surgery is the only effective therapy; reoperation allows survival comparable to that observed in patients without recurrent disease. An aggressive strategy for recurrent ACC is advisable until prospective studies demonstrate a real effectiveness for chemotherapy.

Entities:  

Mesh:

Year:  1997        PMID: 9426440     DOI: 10.1016/s0039-6060(97)90229-4

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  46 in total

1.  Radiofrequency thermal ablation of a splenic metastasis.

Authors:  B J Wood; S Bates
Journal:  J Vasc Interv Radiol       Date:  2001-02       Impact factor: 3.464

Review 2.  Management of adjuvant mitotane therapy following resection of adrenal cancer.

Authors:  M Terzolo; A Ardito; B Zaggia; F Laino; A Germano; S De Francia; F Daffara; A Berruti
Journal:  Endocrine       Date:  2012-06-17       Impact factor: 3.633

3.  Unusual large functional adrenocortical carcinoma in a young woman.

Authors:  Ankur Bansal; Satyanarayan Sankhwar; Ruchir Aeron; Sunny Goel
Journal:  BMJ Case Rep       Date:  2016-01-29

4.  Adrenocortical carcinoma: effect of hospital volume on patient outcome.

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Marco Boniardi; Giorgio De Toma; Luigi Antonio Marzano; Paolo Miccoli; Francesco Minni; Mario Morino; Maria Rosa Pelizzo; Andrea Pietrabissa; Andrea Renda; Andrea Valeri; Carmela De Crea; Rocco Bellantone
Journal:  Langenbecks Arch Surg       Date:  2011-11-09       Impact factor: 3.445

Review 5.  [Systemic therapy of malignant adrenal tumors].

Authors:  M Horstmann; A S Merseburger; A Stenzl; M Kuczyk
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 6.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

7.  Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States.

Authors:  Lauren Gratian; John Pura; Michaela Dinan; Shelby Reed; Randall Scheri; Sanziana Roman; Julie Ann Sosa
Journal:  Ann Surg Oncol       Date:  2014-07-29       Impact factor: 5.344

Review 8.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

9.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

10.  Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.

Authors:  Neda Amini; Georgios Antonios Margonis; Yuhree Kim; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-08-18       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.